Axillary lymph node dissection is the gold standard for staging @entity0 , but it is associated with significant morbidity and complications. Sentinel lymph node mapping technique has demonstrated a successful detection of the node or nodes more likely to have @entity3 . Two techniques are being used to detect @entity1600 -intraoperative use of gamma detecting probe after injection of radio tracer preoperatively and the injection of blue dye and lymphatic mapping intraoperatively. We used both techniques. Twenty-four @entity1 underwent @entity1600 mapping. Blue dye and gamma detecting probe identified sentinel lymph nodes in 78% and 77% of @entity1 , respectively. Overall, 23 of 24 @entity1 had a @entity1600 identified (96%). Ten @entity1 had @entity3 . Out of these ten @entity1 the only positive node/nodes were the @entity1600 in six @entity1 . The other four @entity1 had positive non- @entity1600 along with positive @entity1600 . All of the @entity1 who had @entity3 were detected by the @entity1600 mapping technique. Therefore, no @entity1 had positive non- @entity1600 if the @entity1600 was negative. This technique was 100% predictive of the axillary status. Sentinel lymph node mapping technique will change the management of @entity0 and will allow two-thirds of the @entity1 with @entity0 to be managed without axillary lymph node dissection with a resulting reduction in morbidity and cost.

Sentinel lymph node mapping for staging XXXX : preliminary results of a prospective study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['sentinel lymph node'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastatic disease in the axilla']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
